Please wait while the formulary information is being retrieved.
TYVASO (TREPROSTINIL)
- Pulmonary arterial hypertension
1.74 mg/2.9 mL (0.6 mg/mL) solution for nebulization
- Dosage information is not available
Pulmonary arterial hypertension
- Inhale 0.09 milliliter (54 mcg) via nebulizer by inhalation route 4 times per day at approximately 4 hour intervals
- None
Contraindicated
- None
Severe
Moderate
- gemfibrozil
- Lopid
- None
Contraindicated
- Disease of liver
- Kidney disease with reduction in GFR
Severe
Moderate
- Hypotension
- Increased risk of bleeding
TYVASO (TREPROSTINIL)
- Pulmonary arterial hypertension
- None
- Bone pain
- Cough
- Diarrhea
- Dizziness
- Flushing
- Headache disorder
- Jaw pain
- Nausea
- Pharyngitis
More Frequent
Severe
Less Severe
- Hypotension
- Platelet aggregation inhibition
- Epistaxis
- Syncope
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Hemoptysis
- Hemorrhage
- Pneumonia
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Treprostinil (inh)
Lack of pediatric safety data. No safety and efficacy established.
- 1 Day – 18 Years
- Lack of pediatric safety data. No safety and efficacy established.
Treprostinil (inh, Inj)
- Severity Level:
2
- Additional Notes: Insufficient human data, animal data suggest low risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Treprostinil
Insufficient data available; may be excreted given low molecular wt
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; may be excreted given low molecular wt |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Treprostinil
General-Start at lower doses especially if renal or hepatic insufficiency. Monitor carefully and titrate dosage. Cardiovascular-May cause hypotension, especially with low underlying arterial pressure.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Pulmonary arterial hypertension | |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| 0-9 | A-Z |
|---|---|
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
Formulary Reference Tool